An Open-Label Study To Evaluate the Pharmacodynamic Effects, Efficacy, Safety, and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies or Parkinson's Disease Dementia With or Without Amyloid Copathology

Eisai Clinical Trials

An Open-Label Study To Evaluate the Pharmacodynamic Effects, Efficacy, Safety, and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies or Parkinson’s Disease Dementia With or Without Amyloid Copathology

Protocol # E2027-A001-203

Study Overview

Study Compound: E2027

Drug Name: irsenontrine

Registry #: NCT04764669

Trial Period: Feb 2021 - Jan 2022

Indication: Dementia With Lewy Bodies & Parkinson’s Disease Dementia

Primary Endpoint: 1. Percent Change From Baseline in Cerebrospinal Fluid (CSF) Cyclic Guanosine Monophosphate (cGMP) at Week 9 [Time Frame: Baseline, Week 9]

Population
Males and females 50 Years to 85 Years (Adult, Older Adult)
Study Status
Completed
Study Phase
Phase 2
Countries
Canada, United States See moreSee less

Results

CSR Synopsis

No download available

Lay Summary

Download PDF

Publication reference citation

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

CSDR Sharing is not available for this study.

CSDR	Availability
Clinical Trial Data

Redacted documents may be available upon request for this study.

Document type	Availability
Protocol
SAP
Sample CRF
Full CSR